Prescribing Information & Guidance – BLMKICB Medicines Optimisation

The Bedfordshire, Luton and Milton Keynes Area Prescribing Committee (BLMK APC*) drug bulletins provide information of the clinical effectiveness, cost-effectiveness, safety and impact on the NHS of the drug being examined.

In addition to bulletins assessing specific drugs and indications, other bulletins consider choice of treatment and provide supporting material relating to use and choice of drugs within a treatment pathway. Recommendations made by the JPC can be positive, negative, within agreed criteria or advisory.

* In September 2021, the Bedfordshire and Luton JPC and Milton Keynes PAG formed the BLMK APC.

Please use the search facility to find your relevant guideline or document. Either enter a relevant drug name or medical condition or you can filter by category (This option will list all relevant guidelines specific to the category selected).

Melatonin Prescribing Support Information – For use in Children & Young People

Iron chelation agents for the management of iron overload in transfusion dependent low to intermediate 1 risk myelodysplastic syndrome (MDS)

Primary Care Best Practice Guidance – self-monitoring of blood glucose (SMBG) for adult patients living with type 2 diabetes.

Drospirenone Prescribing Support Information for GPs

Continence Appliance Prescribing Guidelines

Contraception Prescribing Guidance for Primary Care

Emergency Contraception Guidance

Cytisinicline factsheet for prescribers

An Interactive Guide to What Good Looks Like for Assisted Medicine taking

Tirzepatide (Mounjaro®) for Treating Type 2 Diabetes (T2DM) in Adults

SGLT2 Inhibitors in Chronic Kidney Disease (CKD) in Adults

Rimegepant for Acute Treatment of Migraine With or Without Aura in Adults.

Daridorexant Prescribing Support Information

Rybelsus® (oral Semaglutide) Tablets

Guidance for the Treatment and Prevention of Migraine

BLMK Primary Care Prescribing Guidance for SGLT2 inhibitors in Heart Failure with Preserved Ejection Fraction (HFpEF)

Guidance for General Practitioners to support prescribing of Empagliflozin (Jardiance®) for children and young people under 18 years with Type 2 Diabetes (T2DM)

Guidance for General Practitioners to support prescribing of Dulaglutide (Trulicity®) for children and young people under 18 years with Type 2 Diabetes (T2DM)

BLMK ICB – Recommendations for medical devices

Guidance for General Practitioners to support prescribing of Liraglutide for children and young people under 18 years with Type 2 Diabetes (T2DM)

Table of available brands for BIPHASIC Methylphenidate MR Products

Specialist Weight Management Obesity/Bariatric Service Referral Form

BLMK Position Statement on Shared Care with Private Providers

Prescribing Principals in Primary Care for Vitamins and Minerals

Bedford and Luton Primary Care Guidelines for the Management of Chronic Non-Cancer Pain in Adults

Icosapent Ethyl Prescribing Guidance

BLMK Buccal midazolam prescribing guidance

Testosterone for low sexual desire in women – Factsheet

Perinatal Mental Health – Guidance for GPs

BLMK Dry Eye Guidance

Strategies to support reduced Inhaler carbon emissions

Melatonin liquid unlicensed special (Kidmel) example letter

Prescribing guidance – Melatonin unlicensed special (Kidmel)

Use of Nebulised Tobramycin and Nebulised Colistimethate sodium as Antibiotic Prophylaxis to prevent exacerbations of Non- Cystic Fibrosis Bronchiectasis in Adult Patients

Investigation and treatment of Vitamin B12 (cobalamin) deficiency in Adults

Heavy Menstrual Bleeding

Neuropathic pain

Blood Glucose Monitors and Testing Strips

Human Growth Hormone (Somatropin) – Prescribing Support Information

Fluticasone furoate/ Vilanterol (Relvar®Ellipta® ) for the treatment of Asthma (select group of patients)

Rituximab for the treatment of adults with ITP

Rifaximin for the management of chronic diarrhoea associated with gastro intestinal disorders – Bulletin 239 updated July 2016

Rifaximin (Targaxan®) for preventing episodes of overt hepatic encephalopathy (HE)- Bulletin 229 updated July 2016

Rasagiline for the treatment of Parkinson’s disease – Bulletin 285

Ranibizumab or Bevacizumab for the Treatment of Juxtafoveal Telangiectasia

Photodynamic therapy (PDT) with verteporfin (Visudyne®) for chronic central serous retinopathy

Oxygen for Cluster Headaches

Opicapone for Parkinson’s Disease – Bulletin 262

Linezolid Prescriber Information (in Primary care )

Linaclotide for Moderate to Severe Irritable Bowel Syndrome with Constipation

Iron Chelator therapy for the Management of Iron overload in patients with Myelodysplastic syndromes (MDS)

High strength, fixed combination and biosimilar insulin products: minimising the risk of medication error – Safety Reminder

Gabapentin and Pregabalin – Medication Alert (Feb 17)

Drug Monitoring for Sulfasalazine and Mesalazine (Aminosalicylates) in Inflammatory Bowel Disease in Primary Care – Information Sheet

Camouflage Creams – JPC Guidance Statement

Bulletin 282 Revlar Ellipta

Brivaracetam for Epilepsy

Brimonidine tartrate gel (Mirvaso®) for the treatment of facial erythema of rosacea in adult patients

Botulinum Toxin A for the treatment of Upper and Lower Limb Focal Dystonia

Botulinum Toxin A for Ptosis

Bevacizumab – East of England Priorities Advisory Committee (EoEPAC) postion

Household Salt for the Treatment of Umbilical Granuloma

Eflornithine 11.5% cream (Vaniqa®) for the treatment of Hirsutism – JPC Position Statement

Doxylamine succinate and pyridoxine for nausea and vomiting in pregnancy

Discharge Medication for Enhanced Recovery Patients Following Primary Hip and Knee Arthroplasty (L&D Hospital) – Information for GPs

Dapoxetine for the treatment of Premature Ejaculation

Botulinum Toxin A Guidelines – For Multiple Conditions including hyperhidrosis

Bazedoxifene plus conjugated oetsrogens (Duavive®) for post-menopausal symptoms in women with a uterus

Aviptadil/phentolamine intracavernosal injection (Invicorp) for Erectile Dysfunction

Adrenaline Autoinjectors

Flash Glucose Monitoring System patient agreement (Beds and Luton CCG)

Flash Glucose Monitoring System Initiation request from Specialist Team to General Practitioner letter template (NEW PATIENTS)

Flash Glucose Monitoring System Discontinuation request from Specialist Team to General Practitioner letter template (STOPPING FGMS)

Flash Glucose Monitoring System Continuation request from Specialist Team to General Practitioner letter template (POST 6 MONTH REVIEW)

Flash Glucose Monitoring System advice (FAQs) (Bedfordshire CCG and Luton CCG )

Bulletin 272 Gender Identity Services – Primary Care Prescribing Responsibilities for the Hormonal Treatments (including Eflornithine for the Treatment of Hirsutism in this setting) – JPC Position Statement